Majority of Patients with Moderate Aortic Stenosis Carry Features Linked to Twice the Risk of Death, egnite Registry Study Finds
Image File
Original HTML

The analysis, published simultaneously in JACC, found that moderate AS patients with at least one at-risk feature had a two-fold increase in mortality and hospitalization with heart failure compared with moderate AS patients with no at-risk features over two years.

Dr. Philippe Généreux also announced ACTIVATE AS, the first prospective multicenter study to use the CardioCare® platform to identify and follow patients with moderate AS.

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- In a real-world study of more than 53,000 patients with aortic stenosis (AS) at 48 U.S. institutions, moderate AS outnumbered severe AS nearly 2 to 1, and 78.7% of patients with moderate AS had at least one at-risk feature. Over two years, those patients had twice the rate of mortality and hospitalization with heart failure as moderate AS patients without at-risk features, according to data presented today by Philippe Généreux, MD, Director, Structural Heart Program at Atlantic Health Morristown Medical Center, at TCT 2026 San Diego and published simultaneously in the Journal of the American College of Cardiology (JACC).

The study analyzed de-identified data from the egnite Registry, covering nearly 15 million patients and 6.5 million echocardiograms with appropriate permissions, making it the largest study of moderate AS outcomes to date.

Dr. Généreux also announced ACTIVATE AS, a prospective, multicenter study that will use the CardioCare platform to identify approximately 700 patients with moderate AS and follow them rigorously in a dedicated valve clinic with multiparametric evaluation every six months. It is the first prospective clinical study to use CardioCare, with enrollment expected to begin in 2027.

Key findings

Among 53,994 patients with moderate or severe AS identified since January 2022:

- Moderate AS outnumbered severe AS nearly 2 to 1 in this cohort (35,343 vs. 18,651 patients). Of the moderate patients, 78.7% had at least one at-risk feature: valve-related symptoms, left ventricular ejection fraction below 60%, grade 2 or higher diastolic dysfunction, low stroke volume index, atrial fibrillation, or elevated natriuretic peptides. Excluding symptoms, 69.9% still had at least one at-risk feature.

- At-risk features were associated with double the risk of death and hospitalization with heart failure. Two-year mortality was 20.1% for moderate AS patients with at-risk features vs. 9.0% without. Hospitalization with heart failure was 44.6% vs. 21.9%. After multivariable adjustment, including for comorbidities, at-risk features remained associated with roughly twice the risk of death and hospitalization with heart failure.

- Most events occurred while patients were still labeled as moderate. On the last echocardiogram before the event, 86% of hospitalizations with heart failure and 90% of deaths among moderate AS patients occurred while still moderate, without evidence of progression to severe AS.

Current ACC/AHA guidelines recommend echocardiographic surveillance every one to two years for moderate AS, with valve replacement deferred until severe criteria are met. In the study, 20% to 23% of moderate AS patients underwent valve replacement documented by the contributing health system within two years, compared with 50.1% of patients with severe AS.

ACTIVATE AS prospective study

ACTIVATE AS (Activating Patients with Moderate AS) is a prospective, multicenter, observational study of patients with moderate AS. Atlantic Health Morristown Medical Center will serve as the lead site and coordinating center, and enrollment is expected to begin in 2027.

The study will use the CardioCare platform to identify approximately 700 patients with moderate AS across participating sites, grouped by disease phenotype. Patients will be recalled for heart team evaluation, including echocardiography assessed by a core laboratory, natriuretic peptide testing and CT aortic valve calcium scoring. Patients in the study will be followed every six months for up to two years or until they develop severe AS or undergo an aortic valve replacement. ACTIVATE AS is an investigator-initiated study led by Dr. Généreux and funded by an unrestricted grant from Edwards Lifesciences.

"This is CardioCare's first use in a prospective, multicenter study to identify and follow patients, building on the egnite Registry," said Rahul Sharma, MBBS, FRACP, Director of Structural Interventions and Associate Director of the Cardiac Catheterization Laboratory at Stanford Health Care, Senior Medical Advisor of egnite, and co-author of the Moderate Aortic Stenosis with At-risk Features study. "The Registry identifies where risk concentrates in moderate AS; ACTIVATE AS will evaluate these patients in clinical practice through structured assessments and six-month follow-up. Over time, this evidence could help guide monitoring intervals for patients with moderate AS."

About the study

The analysis used de-identified EHR and echocardiographic data from the egnite Registry, covering 14,859,523 patients and 6,514,171 echocardiograms at 48 U.S. institutions with appropriate permissions. It included adults diagnosed with native-valve moderate or severe AS on or after Jan. 1, 2022, and received exemption from Institutional Review Board review. The full manuscript, "Moderate Aortic Stenosis with At-risk Features," is available in JACC.

AS severity was graded from quantitative valve measurements in echocardiography reports according to American Society of Echocardiography guidelines. The analysis was supported by a study grant from Edwards Lifesciences. Findings are observational; full methods and limitations are available in the JACC publication.

About egnite, Inc.

egnite, Inc. is a technology company advancing guideline-directed cardiovascular care and real-world evidence. egnite's CardioCare® platform is deployed at more than 80 heart programs, drawing on data from more than 1,200 cardiovascular care facilities, to identify and prioritize cardiovascular patients. CardioCare combines practical AI, clinical logic aligned to ACC/AHA guidelines and workflow integration to help hospitals move more patients into evidence-based care pathways. The egnite Registry, built on de-identified EHR data with appropriate permissions from 15.7 million patients and 6 million echo reports, gives life sciences and research teams a longitudinal view of the patient journey. The company is headquartered in Aliso Viejo, California. For more information, visit www.egnitehealth.com.

SOURCE egnite Health

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302927060
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): The final paragraph is boilerplate: 'CardioCare is deployed at more than 80 heart programs.' This is a generic corporate/about statement with no news context, taken from the source's About egnite section.
Source Name
Unknown Company
Original Summary

<p>The analysis, published simultaneously in JACC, found that moderate AS patients with at least one at-risk feature had a two-fold increase in mortality and hospitalization with heart failure compared with moderate AS patients with no at-risk features over two years. Dr. Philippe Généreux...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1868077/Egnite-Logo.jpg?id=OA3053975&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Moderate AS Patients With Risk Features Show Double Mortality", "body_html": "<p><strong>SAN DIEGO -- [CURRENT_DATE] --</strong> Moderate aortic stenosis (AS) patients with at least one at-risk feature had twice the two-year rate of death and heart failure hospitalization as moderate AS patients without such features, according to a real-world study of 53,994 patients at 48 U.S. institutions. Philippe Généreux, MD, Director of the Structural Heart Program at Atlantic Health Morristown Medical Center, presented the data at TCT 2026 San Diego. The analysis was published simultaneously in the Journal of the American College of Cardiology (JACC).</p><h5>Moderate AS outnumbers severe AS nearly 2 to 1 in the cohort</h5><p>The cohort comprised 35,343 moderate and 18,651 severe AS patients diagnosed on or after Jan. 1, 2022. Of the moderate patients, 78.7% had at least one at-risk feature. The features were valve-related symptoms, left ventricular ejection fraction below 60%, grade 2 or higher diastolic dysfunction, low stroke volume index, atrial fibrillation, or elevated natriuretic peptides. Excluding symptoms, 69.9% still had at least one.</p><h5>Two-year mortality reaches 20.1% with at-risk features versus 9.0% without</h5><p>Hospitalization with heart failure was 44.6% in moderate patients with at-risk features versus 21.9% in those without. After multivariable adjustment, including for comorbidities, at-risk features remained associated with roughly twice the risk of both outcomes.</p><p>Most events occurred before any documented progression. On the last echocardiogram before the event, 86% of heart failure hospitalizations and 90% of deaths among moderate AS patients occurred while the patient was still classed as moderate.</p><h5>Valve replacement rates for moderate AS patients stay at 20% to 23%</h5><p>Current ACC/AHA guidelines call for echocardiographic surveillance every one to two years in moderate AS, with valve replacement deferred until severe criteria are met. Within two years, 20% to 23% of moderate AS patients underwent valve replacement documented by the contributing health system, compared with 50.1% of severe AS patients.</p><h5>egnite Registry data covers 14,859,523 patients and 6,514,171 echocardiograms</h5><p>The study used de-identified EHR and echocardiographic data from the egnite Registry, which the source describes as the largest study of moderate AS outcomes to date. AS severity was graded from quantitative echocardiography measurements under American Society of Echocardiography guidelines. The study received an exemption from Institutional Review Board review and was supported by a study grant from Edwards Lifesciences. The findings are observational.</p><h5>ACTIVATE AS will enroll about 700 moderate AS patients from 2027</h5><p>Généreux also announced ACTIVATE AS (Activating Patients with Moderate AS), a prospective, multicenter, observational study. It is the first prospective clinical study to use egnite's CardioCare platform. The platform will identify roughly 700 moderate AS patients across participating sites and group them by disease phenotype. Atlantic Health Morristown Medical Center will serve as lead site and coordinating center, and enrollment is expected to begin in 2027.</p><p>Patients will be recalled for heart team evaluation, including echocardiography assessed by a core laboratory, natriuretic peptide testing and CT aortic valve calcium scoring. They will be followed every six months for up to two years, or until they develop severe AS or undergo aortic valve replacement. The investigator-initiated study is funded by an unrestricted grant from Edwards Lifesciences.</p><p>Rahul Sharma, MBBS, FRACP, of Stanford Health Care, a Senior Medical Advisor of egnite and co-author of the JACC paper, said the registry identifies where risk concentrates in moderate AS, while \"ACTIVATE AS will evaluate these patients in clinical practice.\" He said the evidence could help guide monitoring intervals.</p><p>CardioCare is deployed at more than 80 heart programs.</p>", "meta_description": "Study of 53,994 aortic stenosis patients finds 78.7% with moderate disease carry at-risk features, doubling two-year mortality; ACTIVATE AS trial starts 2027.", "seo_keywords": "aortic stenosis, moderate AS, egnite Registry, CardioCare, ACTIVATE AS, TCT 2026, JACC, Edwards Lifesciences, heart failure hospitalization, structural heart", "companies": ["egnite", "Edwards Lifesciences", "Atlantic Health Morristown Medical Center"], "industries": ["Healthcare & Biotech"], "markets_regions": ["United States"], "news_type": ["research_publication", "clinical_study_announcement"], "products": ["CardioCare"], "themes": ["real_world_evidence", "cardiovascular_care", "clinical_research"], "events": ["TCT 2026"], "cta_text": "Learn more about egnite's CardioCare platform and egnite Registry", "learn_more": "https://www.egnitehealth.com", "fact_check": {"accuracy_score": 98, "legal_risk": "low", "corrections_made": ["Corrected garbled character encoding in physician name", "Used [CURRENT_DATE] placeholder in dateline per instructions"], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
93a383cf65092e746e19ef53fa34929f
Company Website
Company Website